Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation

Journal of Cellular Physiology

Volumn 208, Issue 1, 2006, Pages 220-228

  Servidei, Tiziana ^a   Riccardi, Anna ^a   Sanguinetti, Maurizio ^a   Dominici, Carlo ^b,c,d   Riccardi, Riccardo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CARMUSTINE; CISPLATIN; ETOPOSIDE; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN KINASE B; VINCRISTINE;

ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CHEMOSENSITIVITY; ENZYME ACTIVATION; GENE TARGETING; GLIOMA CELL; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; MALIGNANT TRANSFORMATION; MITOGENESIS; NEUROBLASTOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TARGET CELL; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEUROBLASTOMA; OVARIAN NEOPLASMS; PHOSPHORYLATION; PIPERAZINES; PLATELET-DERIVED GROWTH FACTOR; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 33744931651     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.20659     Document Type: Article

References (36)

1. Brandes AA. 2003. State-of-the-art treatment of high-grade brain tumors. Semin Oncol 30 (6 Suppl 19):4-9.
2. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, Lydon NB. 2000. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295(1):139-145.
3. Chakravarti A, Chakladar A, Delaney MA, Latham DE, Loeffler JS. 2002. The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner. Cancer Res 62(15):4307-4315.
4. Chu S, Holtz M, Gupta M, Bhatia R. 2004. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells. Blood 103(8):3167-3174.
5. Dai Q, Ling YH, Lia M, Zou YY, Kroog G, Iwata KK, Perez-Soler R. 2005. Enhanced sensitivity to the HER1/Epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines. Clin Cancer Res 11(4):1572-1578.
6. Deininger MW, Druker BJ. 2003. Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev 55(3):401-423.
7. Dresemann G. 2005. Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: A patient series. Ann Oncol 16(10):1702-1708.
8. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB. 1996. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2(5):561-566.
9. Engelman JA, Janne PA, Mermel C, Pearlberg J, Mukohara T, Fleet C, Cichowski K, Johnson BE, Cantley LC. 2005. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci USA 102(10):3788-3793.
10. Fredriksson L, Li H, Eriksson U. 2004. The PDGF family: Four gene products form five dimeric isoforms. Cytokine Growth Factor Rev 15(4):197-204.
11. Goldman JM, Melo JV. 2003. Chronic myeloid leukemia-advances in biology and new approaches to treatment. N Engl J Med 349(15):1451-1464.
12. Guo P, Hu B, Gu W, Xu L, Wang D, Huang HJ, Cavenee WK, Cheng SY. 2003. Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. Am J Pathol 162(4):1083-1093.
13. Heldin CH, Westermark B. 1999. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79(4):1283-1316.
14. Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G. 2002. Management of malignant gastrointestinal stromal tumours. Lancet Oncol 3(11):655-664.
15. Johnson FM, Saigal B, Donato NJ. 2005. Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells. J Cell Physiol 205(2):218-227.
16. Katayama H, Tabata M, Kiura K, Hotta K, Kozuki T, Hisamoto A, Kishino D, Takigawa N, Ueoka H, Tanimoto M. 2004. Sensitization of non-small cell lung cancer to Gefitinib after cisplatin treatment is associated with reconnection of EGFR phosphorylation and PI3K/Akt signaling pathway. Proc AACR [Abstract 4652] 45:1074.
17. Kilic T, Alberta JA, Zdunek PR, Acar M, Iannarelli P, O'Reilly T, Buchdunger E, Black PM, Stiles CD. 2000. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res 60(18):5143-5150.
18. Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK, DePinho RA. 2001. Malignant glioma: Genetics and biology of a grave matter. Genes Dev 15(11):1311-1333.
19. Matei D, Chang DD, Jeng MH. 2004. Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation. Clin Cancer Res 10(2):681-690.
20. Meijerink J, Mandigers C, van de Locht L, Tonnissen E, Goodsaid F, Raemaekers J. 2001. A novel method to compensate for different amplification efficiencies between patient DNA samples in quantitative real-time PCR. J Mol Diagn 3(2):55-61.
21. Nagane M, Levitzki A, Gazit A, Cavenee WK, Huang HJ. 1998. Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc Natl Acad Sci USA 95(10):5724-5729.
22. Newton HB. 2003. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: Growth factor and Ras signaling pathways. Expert Rev Anticancer Ther 3(5):595-614.
23. Peirson SN, Butler JN, Foster RG. 2003. Experimental validation of novel and conventional approaches to quantitative real-time PCR data analysis. Nucleic Acids Res 31(14):e73.
24. Pfaffl MW. 2001. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29(9):e45.
25. Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW. 2004. Apoptosis defects and chemotherapy resistance: Molecular interaction maps and networks. Oncogene 23(16):2934-2949.
26. Potapova O, Fakhrai H, Baird S, Mercola D. 1996. Platelet-derived growth factor-B/v-sis confers a tumorigenic and metastatic phenotype to human T98G glioblastoma cells. Cancer Res 56(2):280-286.
27. Servidei T, Ferlini C, Riccardi A, Meco D, Scambia G, Segni G, Manzotti C, Riccardi R. 2001. The novel trinuclear platinum complex BBR3464 induces a cellular response different from cisplatin. Eur J Cancer 37(7):930-938.
28. Shamah SM, Stiles CD, Guha A. 1993. Dominant-negative mutants of platelet-derived growth factor revert the transformed phenotype of human astrocytoma cells. Mol Cell Biol 13(12):7203-7212.
29. Shih AH, Dai C, Hu X, Rosenblum MK, Koutcher JA, Holland EC. 2004. Dose-dependent effects of platelet-derived growth factor-B on glial tumorigenesis. Cancer Res 64(14):4783-4789.
30. Siddik ZH. 2003. Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene 22(47):7265-7279.
31. Sorkin A, Westermark B, Heldin CH, Claesson-Welsh L. 1991. Effect of receptor kinase inactivation on the rate of internalization and degradation of PDGF and the PDGF beta-receptor. J Cell Biol 112(3):469-478.
32. Strawn LM, Mann E, Elliger SS, Chu LM, Germain LL, Niederfellner G, Ullrich A, Shawver LK. 1994. Inhibition of glioma cell growth by a truncated platelet-derived growth factor-beta receptor. J Biol Chem 269(33):21215-21222.
33. Uhrbom L, Hesselager G, Nister M, Westermark B. 1998. Induction of brain tumors in mice using a recombinant platelet-derived growth factor B-chain retrovirus. Cancer Res 58(23):5275-5279.
34. Vitali R, Cesi V, Nicotra MR, McDowell HP, Donfrancesco A, Mannarino O, Natali PG, Raschella G, Dominici C. 2003. c-Kit is preferentially expressed in MYCN-amplified neuroblastoma and its effect on cell proliferation is inhibited in vitro by STI-571. Int J Cancer 106(2):147-152.
35. West KA, Castillo SS, Dennis PA. 2002. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat 5(6):234-248.
36. Yu C, Krystal G, Varticovksi L, McKinstry R, Rahmani M, Dent P. 2002. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells. Cancer Res 62(1):188-199.